What the Clinical Record Actually Showed: LSD Therapy 1947-1968

“Over a thousand published papers. Forty thousand patients. Roughly fifty percent of treated alcoholics achieving lasting sobriety. The program was not stopped because it failed.”

When the Schedule I designation for LSD took effect with the 1970 Controlled Substances Act, it ended a clinical research program that had been running for twenty-three years and had produced results that no subsequent psychiatric intervention has matched in several key areas.

The program began in 1947 when the manufacturer first distributed LSD to psychiatric researchers under a trade name. The accompanying package insert described two potential research applications: as a model of psychosis (for training clinicians in the phenomenology of schizophrenia), and as a treatment for various neurotic conditions by facilitating the surfacing and processing of psychological material.

By 1965, when the manufacturer withdrew its LSD product in response to the counterculture controversy, the clinical literature encompassed over one thousand published papers and reports from dozens of research centers. The patient population was heterogeneous: alcoholics, end-of-life anxiety patients, treatment-resistant depressives, and patients with neurotic disorders of various kinds.

The most robust results came from the alcoholism trials. Hoffer, Osmond and colleagues in Saskatchewan treated many alcoholic patients with LSD-assisted therapy in the 1950s and reported that roughly half improved or stopped drinking (for example Chwelos and colleagues, Quarterly Journal of Studies on Alcohol, 1959). These were uncontrolled reports, and later controlled trials found smaller effects. Their methodology was not by modern standards rigorous, the trials were not randomized and controlled by current criteria, but the consistency of the result across variations in method was sufficient for serious clinical attention.

A 2012 meta-analysis by Krebs and Johansen (Journal of Psychopharmacology) pooled six randomized controlled trials of LSD for alcoholism (536 participants) and found a significant beneficial effect on alcohol misuse, clearest at the earlier follow-ups. The meta-analysis was limited by the quality of the original trials, but its conclusion, that the effect was real and clinically meaningful, was consistent with the broader clinical record.

The end-of-life anxiety results were comparable. Early trials by Walter Pahnke, Sidney Cohen, and others found that LSD-assisted therapy significantly reduced death anxiety in terminal cancer patients and was associated with reported acceptance of death rather than dread. The mechanism, in Pahnke's account, was the mystical experience: patients who had complete mystical experiences during sessions showed the greatest reduction in anxiety.

This finding, that mystical experience quality predicts therapeutic outcome, has been confirmed in the current psilocybin research (Barrett & Griffiths, 2018; Yaden & Griffiths, 2021) and is one of the most consistent findings across the fifty-year interruption. What was established in the LSD trials of the 1950s and 1960s, lost in the prohibition, and reestablished in the psilocybin trials of the 2010s and 2020s, is: the mechanism of psychedelic-assisted therapy is the quality of the consciousness it occasions, not only the pharmacology.

What was stopped in 1968-1970 was not a research program that had reached its natural conclusion. It was a research program in full development, accumulating positive results, refining its methodology, and approaching the stage at which it might have produced regulatory submissions for specific indications.

The industry Phase 3 trials of synthetic psilocybin, reporting in 2025 and 2026, are the research program that the 1970 Controlled Substances Act would have produced forty years earlier if it had not been halted. The clinical evidence for psychedelic-assisted therapy for depression and end-of-life anxiety is now, as of 2026, at Phase 3 quality. This evidence would have existed by approximately 1985 if the program had continued uninterrupted.

Hofmann knew what was being lost in 1968. He had watched the clinical program from inside the company, contributed to it through his pharmacological analysis, and understood its potential. My Problem Child is partly a document of grief: grief for a research program that was working, for patients who needed it, for a medical opportunity that political decisions eliminated.

Sources

• Hofmann, LSD: My Problem Child (1979)
• Krebs & Johansen, Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials, J Psychopharmacol (2012)
• Hoffer & Osmond, J. Mental Sci. (1961) [Source not found; under review]
• Stevens, Storming Heaven (1987)
• Medical History of Psychedelic Drugs, Cambridge HPS dissertation (2007) [Source not found; under review]
• Chwelos, Blewett, Smith & Hoffer, Quarterly Journal of Studies on Alcohol (1959)